154 related articles for article (PubMed ID: 29994904)
21. A glycolytic phenotype is associated with prostate cancer progression and aggressiveness: a role for monocarboxylate transporters as metabolic targets for therapy.
Pertega-Gomes N; Felisbino S; Massie CE; Vizcaino JR; Coelho R; Sandi C; Simoes-Sousa S; Jurmeister S; Ramos-Montoya A; Asim M; Tran M; Oliveira E; Lobo da Cunha A; Maximo V; Baltazar F; Neal DE; Fryer LG
J Pathol; 2015 Aug; 236(4):517-30. PubMed ID: 25875424
[TBL] [Abstract][Full Text] [Related]
22. Glutaminase regulation in cancer cells: a druggable chain of events.
Katt WP; Cerione RA
Drug Discov Today; 2014 Apr; 19(4):450-7. PubMed ID: 24140288
[TBL] [Abstract][Full Text] [Related]
23. Glutamine addiction activates polyglutamine-based nanocarriers delivering therapeutic siRNAs to orthotopic lung tumor mediated by glutamine transporter SLC1A5.
Wang C; Wu J; Wang Z; Yang Z; Li Z; Deng H; Li L; Peng X; Feng M
Biomaterials; 2018 Nov; 183():77-92. PubMed ID: 30149232
[TBL] [Abstract][Full Text] [Related]
24. Drug discovery strategies in the field of tumor energy metabolism: Limitations by metabolic flexibility and metabolic resistance to chemotherapy.
Amoedo ND; Obre E; Rossignol R
Biochim Biophys Acta Bioenerg; 2017 Aug; 1858(8):674-685. PubMed ID: 28213330
[TBL] [Abstract][Full Text] [Related]
25. 2-Amino-4-bis(aryloxybenzyl)aminobutanoic acids: A novel scaffold for inhibition of ASCT2-mediated glutamine transport.
Schulte ML; Khodadadi AB; Cuthbertson ML; Smith JA; Manning HC
Bioorg Med Chem Lett; 2016 Feb; 26(3):1044-1047. PubMed ID: 26750251
[TBL] [Abstract][Full Text] [Related]
26. Targeting Glutamine Induces Apoptosis: A Cancer Therapy Approach.
Chen L; Cui H
Int J Mol Sci; 2015 Sep; 16(9):22830-55. PubMed ID: 26402672
[TBL] [Abstract][Full Text] [Related]
27. SLC1A5 Silencing Inhibits Esophageal Cancer Growth via Cell Cycle Arrest and Apoptosis.
Lin J; Yang T; Peng Z; Xiao H; Jiang N; Zhang L; Ca D; Wu P; Pan Q
Cell Physiol Biochem; 2018; 48(1):397. PubMed ID: 30071532
[TBL] [Abstract][Full Text] [Related]
28. Molecular targeting of glutaminase sensitizes ovarian cancer cells to chemotherapy.
Masamha CP; LaFontaine P
J Cell Biochem; 2018 Jul; 119(7):6136-6145. PubMed ID: 29633308
[TBL] [Abstract][Full Text] [Related]
29. Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment.
Tanaka K; Sasayama T; Irino Y; Takata K; Nagashima H; Satoh N; Kyotani K; Mizowaki T; Imahori T; Ejima Y; Masui K; Gini B; Yang H; Hosoda K; Sasaki R; Mischel PS; Kohmura E
J Clin Invest; 2015 Apr; 125(4):1591-602. PubMed ID: 25798620
[TBL] [Abstract][Full Text] [Related]
30. Glutamine Skipping the Q into Mitochondria.
Stine ZE; Dang CV
Trends Mol Med; 2020 Jan; 26(1):6-7. PubMed ID: 31866300
[TBL] [Abstract][Full Text] [Related]
31. Targeting Key Transporters in Tumor Glycolysis as a Novel Anticancer Strategy.
Shi Y; Liu S; Ahmad S; Gao Q
Curr Top Med Chem; 2018; 18(6):454-466. PubMed ID: 29788889
[TBL] [Abstract][Full Text] [Related]
32. Let-7 Suppresses B Cell Activation through Restricting the Availability of Necessary Nutrients.
Jiang S; Yan W; Wang SE; Baltimore D
Cell Metab; 2018 Feb; 27(2):393-403.e4. PubMed ID: 29337138
[TBL] [Abstract][Full Text] [Related]
33. Glutaminase isoenzymes in the metabolic therapy of cancer.
Matés JM; Campos-Sandoval JA; Márquez J
Biochim Biophys Acta Rev Cancer; 2018 Dec; 1870(2):158-164. PubMed ID: 30053497
[TBL] [Abstract][Full Text] [Related]
34. Glutamine promotes escape from therapy-induced senescence in tumor cells.
Pacifico F; Badolati N; Mellone S; Stornaiuolo M; Leonardi A; Crescenzi E
Aging (Albany NY); 2021 Sep; 13(17):20962-20991. PubMed ID: 34492636
[TBL] [Abstract][Full Text] [Related]
35. Glutamine deficiency induces DNA alkylation damage and sensitizes cancer cells to alkylating agents through inhibition of ALKBH enzymes.
Tran TQ; Ishak Gabra MB; Lowman XH; Yang Y; Reid MA; Pan M; O'Connor TR; Kong M
PLoS Biol; 2017 Nov; 15(11):e2002810. PubMed ID: 29107960
[TBL] [Abstract][Full Text] [Related]
36. Trabectedin suppresses escape from therapy-induced senescence in tumor cells by interfering with glutamine metabolism.
Pacifico F; Mellone S; D'Incalci M; Stornaiuolo M; Leonardi A; Crescenzi E
Biochem Pharmacol; 2022 Aug; 202():115159. PubMed ID: 35780827
[TBL] [Abstract][Full Text] [Related]
37. ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer.
van Geldermalsen M; Wang Q; Nagarajah R; Marshall AD; Thoeng A; Gao D; Ritchie W; Feng Y; Bailey CG; Deng N; Harvey K; Beith JM; Selinger CI; O'Toole SA; Rasko JE; Holst J
Oncogene; 2016 Jun; 35(24):3201-8. PubMed ID: 26455325
[TBL] [Abstract][Full Text] [Related]
38. ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis.
Lu H; Li X; Lu Y; Qiu S; Fan Z
Cancer Lett; 2016 Oct; 381(1):23-30. PubMed ID: 27450723
[TBL] [Abstract][Full Text] [Related]
39. Recent Development of Small Molecule Glutaminase Inhibitors.
Song M; Kim SH; Im CY; Hwang HJ
Curr Top Med Chem; 2018; 18(6):432-443. PubMed ID: 29793408
[TBL] [Abstract][Full Text] [Related]
40. Targeting metabolic vulnerabilities of cancer: Small molecule inhibitors in clinic.
Tripathi SC; Fahrmann JF; Vykoukal JV; Dennison JB; Hanash SM
Cancer Rep (Hoboken); 2019 Feb; 2(1):e1131. PubMed ID: 32721114
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
